New research suggests that the weight-loss medication Mounjaro may not be a worthwhile investment at its present cost. The study highlights concerns about the drug's value in relation to its price. Cost-effectiveness is questioned.
A recent study indicates that the weight-loss drug Mounjaro may not represent good value for money at its current price point.
The findings suggest that the cost of Mounjaro may outweigh its benefits for some individuals, raising questions about its overall cost-effectiveness.
Track your medication journey
Join thousands using Shotlee to track GLP-1 medications.
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Health tracking apps like Shotlee can help monitor weight loss progress when using medications like Mounjaro, but the initial cost needs to be justified.
Original source: Breaking News.ie
View original article →Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.
New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.
Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.
